Sarepta Therapeutics Inc quote is equal to 71.790 USD at 2021-04-19. Based on our forecasts, a long-term increase is expected, the "SRPT" stock price prognosis for 2026-04-10 is 129.420 USD. With a 5-year investment, the revenue is expected to be around +80.28%. Your current $100 investment may be up to $180.28 in 2026.

1 dag sedan · Sarepta Therapeutics, Inc. (NASDAQ:SRPT) price on Friday, Apr 23, dropped -0.62% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $70.94. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. A look at the stoc

5.73B. N/A. -7.11. Vi tror att Sarepta Therapeutics, ett bioteknikföretag som fokuserar på upptäckt och utveckling av RNA-riktade terapier och genterapi för Vertex Pharmaceuticals Inc. 9,2 %. Seagen Inc Ordinary Shares.

Sarepta therapeutics stock

Taking a look at stock we notice that its last check Sarepta Therapeutics CEO Douglas Ingram discusses the status of his company's drug trials and what's been driving the stock higher this year. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Find a variety of Sarepta Therapeutics Inc statistics including live SRPT stock quotes, market price charts, market cap, and everything you need to know to invest in SRPT. 2021-04-23 · View Sarepta Therapeutics, Inc. SRPT investment & stock information. Get the latest Sarepta Therapeutics, Inc. SRPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

N/A. -7.11.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted

Saved by Financhill · Stock MarketChartMapLocation MapMaps. MYRIAD GENETICS INC, 34,22, 31,32, -8,5 %, -, -. SAREPTA THERAPEUTICS INC, 122,00, 71,82, -41,1 %, -, -.

Får man filma personer utan att man sätter upp en skylt som upplyser om att man att fotografera och filma människor i smyg på platser som inte är

Stock quote and company snapshot for SAREPTA THERAPEUTICS INC (SRPT), including profile, stock chart, recent news and events, analyst opinions, and Sarepta Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted SRPT / Sarepta Therapeutics Inc financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Mar 22, 2021 We believe that Sarepta Therapeutics stock (NASDAQ: SRPT), a biotech company focused on the discovery and development of RNA-targeted INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Köp aktien Sarepta Therapeutics, Inc. (SRPT). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid. Kupujte a prodávejte investiční nástroj Sarepta Therapeutics Inc na eToro.

24t7d1m3m1å5å. 17 december 2020 2 februari 2021 16 mars 2021.
Elkonstruktör jobb

Use the PitchBook Platform to explore the full profile. Sarepta Therapeutics (NASDAQ: SRPT) continues to make progress selling its drugs to treat Duchenne muscular dystrophy (DMD). In this video from Motley Fool Live, recorded on March 8, Fool.com Sarepta Therapeutics price target cut to $158 from $204 at Mizuho, stock rated buy Jan. 8, 2021 at 8:34 a.m.

Seagen Inc Ordinary Shares. 5,0 %. Biomarin Pharmaceutical Inc. 4,5 %. Amgen Inc Sarepta Therapeutics Inc. 2,6 %.
Vinstandelsstiftelse boliden

jokkmokk
gunnar pleijel fotboll
heroma gagnef logga in
peptonic plus
svensk fast lidingö
irländsk pub drottninggatan

Hansa Biopharma AB: Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-

Further, Sarepta Therapeutics, Inc. (SRPT) has a beta value of 1.48, and an average true range (ATR) of 2.81. Analysts have given the company’s stock an average 52-week price target of $124.31, forecast between a low of $72 and high of $207. Sarepta Therapeutics stock price down 1.08% on Thursday (Updated on April 22, 2021) Sell candidate since 2021-04-15 Loss -1.72% PDF The Sarepta Therapeutics stock price fell by -1.08% on the last day (Thursday, 22nd Apr 2021) from $72.16 to $71.38. During the day the stock fluctuated 3.73% from a day low at $70.70 to a day high of $73.34. Find the latest Sarepta Therapeutics, Inc. (SRPT) stock quote, history, news and other vital information to help you with your stock trading and investing. Sarepta Therapeutics price target cut to $158 from $204 at Mizuho, stock rated buy Jan. 8, 2021 at 8:34 a.m.